• Low-Molecular Weight Inhibitors Targeting Alternative Comple

  2026-08-04

  The reference study provides a comprehensive overview of the development and mechanistic understanding of low-molecular weight inhibitors targeting the alternative complement pathway, focusing on the therapeutic potential of factor B and factor D inhibitors. Its findings have significant implications for advancing complement-mediated disease research and developing targeted interventions.

• SR-202 in Translational Metabolic and Inflammatory Research

  2026-08-03

  Explore how SR-202, a selective PPARγ antagonist, is reshaping insulin resistance research and anti-obesity drug development through advanced mechanistic insights. Discover its unique utility in bridging metabolic and inflammatory pathways for next-generation applications.

• TH287 MTH1 Inhibitor Enhances Radiosensitivity in CRPC Cells

  2026-08-03

  The reference study demonstrates that the MTH1 inhibitor TH287 significantly increases the susceptibility of castration-resistant prostate cancer (CRPC) cells to ionizing radiation. By optimizing the sequencing of TH287 and radiation, the research provides actionable protocols for radiosensitization and highlights the mechanistic basis for selective tumor cell cytotoxicity.

• Stattic: STAT3 Inhibitor Workflows for Cancer and Lymphangio

  2026-08-02

  Stattic, a potent STAT3 inhibitor from APExBIO, empowers researchers to dissect STAT3-mediated signaling in both cancer and vascular biology. This guide delivers detailed workflows, troubleshooting insights, and translational strategies for maximizing experimental success in STAT3-driven apoptosis, radiosensitization, and lymphangiogenesis.

• SETD7 Depletion Promotes White Fat Browning and Metabolic He

  2026-08-01

  This study uncovers SETD7 as a negative regulator of thermogenic gene expression in white adipose tissue. Depleting SETD7 in obese mice enhances white adipose browning and improves systemic metabolic parameters, offering a mechanistic advance and potential therapeutic target for obesity-related disorders.

• GI 254023X: Advanced ADAM10 Inhibitor for Vascular & Cell As

  2026-07-31

  GI 254023X sets a new benchmark as a selective ADAM10 inhibitor, providing precise control over cell signaling and endothelial integrity. Its proven workflow flexibility and robust selectivity offer researchers a reliable edge for dissecting apoptosis, Notch1 signaling, and vascular responses in complex models.

• Iptacopan Monotherapy Rapidly Reduces Hemolysis in PNH: Phas

  2026-07-31

  This open-label phase 2 study demonstrates that oral Iptacopan (LNP023) monotherapy achieves rapid, durable reductions in hemolytic markers and transfusion requirements in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients. The findings establish alternative pathway factor B inhibition as a promising, well-tolerated therapeutic strategy for complement-mediated diseases.

• Sodium Salicylate as an NF-κB Inhibitor: Beyond Stroma Modul

  2026-07-30

  Explore the multifaceted role of sodium salicylate as a potent NF-κB inhibitor in inflammation and tumor microenvironment research. Discover unique mechanistic insights, advanced assay strategies, and practical applications that extend beyond conventional stroma modulation.

• EZ Cap™ Human PTEN mRNA: Next-Gen Strategies for Functional

  2026-07-30

  Explore how EZ Cap™ Human PTEN mRNA enables precision restoration of tumor suppressor gene function for advanced cancer research. This article uniquely dissects cap structure, delivery innovations, and translational workflow optimization, offering actionable insights for cutting-edge gene therapy research.

• Iptacopan Monotherapy Rapidly Improves Hemolysis in PNH: Pha

  2026-07-29

  This study demonstrates that oral Iptacopan (LNP023) monotherapy produces rapid, durable improvements in hemolytic markers and hemoglobin levels for patients with paroxysmal nocturnal hemoglobinuria (PNH), reducing transfusion requirements without serious adverse effects. These findings significantly advance oral complement factor B inhibition as a targeted therapeutic strategy for complement-mediated diseases.

• GSK126 EZH2 Inhibitor: Translational Leverage in Cancer Epig

  2026-07-29

  Explore how GSK126, a highly selective EZH2 inhibitor from APExBIO, empowers translational researchers to interrogate and therapeutically modulate PRC2-driven epigenetic silencing in cancer. This article synthesizes mechanistic rationale, workflow guidance, and strategic perspectives—bridging evidence from pan-cancer analyses and emerging clinical insights to inform the next wave of oncology drug development.

• Resiniferatoxin (RTX): Mechanistic Insights and Translationa

  2026-07-28

  Explore the advanced mechanism and diverse applications of Resiniferatoxin (RTX) as a TRPV1-targeted analgesic. This article offers a deep dive into RTX’s cellular actions, recent reference-backed findings, and unique roles in pain and inflammation research.

• Entinostat (MS-275): Enhancing Cancer Cell Inhibition Protoc

  2026-07-28

  Entinostat (MS-275) transforms cancer research by providing selective, potent HDAC1/3 inhibition, enabling precise modulation of proliferation and apoptosis in diverse tumor models. This article details optimized workflows, troubleshooting strategies, and translational insights that set Entinostat apart as an indispensable tool for advanced oncology research.

• MDV3100 (Enzalutamide): Optimizing Prostate Cancer Workflows

  2026-07-27

  MDV3100 (Enzalutamide) is redefining androgen receptor pathway research by enabling precise modulation, apoptosis induction, and resistance modeling in prostate cancer. From robust in vitro protocols to troubleshooting context-dependent senescence, this guide leverages the latest evidence and APExBIO’s trusted supply to maximize experimental impact.

• VER 155008: Redefining HSP70 Inhibition in Cancer and Neurod

  2026-07-27

  Explore how VER 155008, a leading HSP 70 inhibitor, unlocks new insights into apoptosis and phase separation in cancer and neurodegeneration. This article delivers unique mechanistic depth and translational context for advanced cancer research.

3711 records 7/248 page Previous Next First page 上5页 678910 下5页 Last page